(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
With enpatoran soon entering Phase III clinical trials, the Phase II safety and efficacy results support the drug’s development.
He has been adjusting the stock market-listed fund's portfolio to make it fit for purpose in a world where higher inflation ...
Nanobiotix S.A. (NASDAQ:NBTX) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good day, and thank you for standing ...
S&P 500 slides 7.5% YTD in 2026 as Magnificent Seven stocks drag markets lower; see biggest decliners, breadth stats, and ETF ...
The S&P/ASX 200 Healthcare Index fell 6.29% in March as the broader S&P/ASX 200 slumped 7.15% as global markets felt the ...
New research into the Middle East and Africa (MEA) region from Group-IB, a leading creator of cybersecurity technologies to ...
Neuraxis Inc. company and executive profile by Barron's. View the latest NRXS company infomation and executive bios.
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA ...
The investment seeks to track the investment results of the BlackRock Interest Rate Hedged Long-Term Corporate Bond Index designed to minimize the interest rate exposure of a portfolio composed of U.S ...
The investment seeks to track the investment results of the ICE 2027 Maturity U.S. Inflation-Linked Treasury Index composed of inflation-protected U.S. Treasury bonds maturing in 2027. The index ...
Copyright © 2026 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results